[CAS NO. 61350-00-3] VU 0364770
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [61350-00-3]
Catalog
SLK-S2862
Brand
Selleck
CAS
61350-00-3
DESCRIPTION [61350-00-3]
Overview
| MDL | MFCD00548412 |
|---|---|
| Molecular Weight | 232.67 |
| Molecular Formula | C12H9ClN2O |
| SMILES | O=C(C1=NC=CC=C1)NC2=CC=CC(Cl)=C2 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2979 mL | 21.4897 mL | 42.9793 mL |
| 5 mM | 0.8596 mL | 4.2979 mL | 8.5959 mL |
| 10 mM | 0.4298 mL | 2.1490 mL | 4.2979 mL |
| 50 mM | 0.0860 mL | 0.4298 mL | 0.8596 mL |
Description
VU 0364770 is a positive allosteric modulator(PAM) of with of 1.1 μM, exhibits insignificant activity at 68 other receptors, including other mGlu subtypes.
Targets
| mGlu4 [1] |
| 1.1 μM(EC50) |
In vitro
VU0364770 is a potent and effective positive allosteric modulator of mGlu4. VU0346770 exhibits a potency of 1.1 ± 0.2 μM at human mGlu4 in the presence of an EC20 concentration of glutamate and shifts the glutamate concentration-response curve 31.4 ± 4.0-fold to the left. VU0364770 exhibits a potency of 290 ± 80 nM at rat mGlu4 and induces an 18.1 ± 1.7-fold left shift of the glutamate concentration-response curve.
In vivo
VU0364770 shows efficacy alone or when administered in combination with l-DOPA or an adenosine 2A (A2A) receptor antagonist preladenant currently in clinical development. When administered alone, VU0364770 exhibits efficacy in reversing haloperidol-induced catalepsy, forelimb asymmetry-induced by unilateral 6-hydroxydopamine (6-OHDA) lesions of the median forebrain bundle, and attentional deficits induced by bilateral 6-OHDA nigrostriatal lesions in rats. In addition, VU0364770 enhances the efficacy of preladenant to reverse haloperidol-induced catalepsy when given in combination. The effects of VU0364770 to reverse forelimb asymmetry are also potentiated when the compound is coadministered with an inactive dose of l-DOPA, suggesting that mGlu4 positive allosteric modulator may provide l-DOPA-sparing activity.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.